Clinical Research Directory

Inclusion Criteria: * Language spoken: Finnish, English or Swedish * Mental status: Patients must be able to understand the meaning of the study * Informed consent: The patient must sign the appropriate Ethics Committee (EC) approved informed consent documents in the presence of the designated staff. * Biopsy-confirmed acinar adenocarcinoma of the prostate * Gleason score ≥ 3+4/International Society of Urological Pathology grade group ≥ 2 * High volume Gleason score 6 as determined on biopsies (\>2 positive cancer core or ≥ 50% cancer in a core) * Patient presenting low volume Gleason score 6 disease and refuses active surveillance * Non-metastatic disease; high-risk patients according to European Association of Urology risk group stratification will undergo F-Prostate specific membrane antigen-Positron Emission Tomography/Computer Tomography to exclude distant metastasis * Lesion visible on MRI (Prostate Imaging Reporting and Data System v2 4-5) * Eligible for general anesthesia (American Society of Anesthesiologists (ASA)≤ 3) Exclusion Criteria: * Contraindications for MRI (cardiac pacemaker, intracranial clips etc.) * Acute unresolved urinary tract infection * Claustrophobia * Hip replacement surgery or other metal in the pelvic area * Known allergy to gadolinium * Inability to insert urinary catheter * Suspected tumor on baseline MRI further than 30 mm or within 3 mm of the prostatic urethra * Prostate calcifications or cysts obstructing planned ultrasound beam path within the targeted tissue volume * Any other conditions that might compromise patient safety, based on the clinical judgment of the responsible urologist